Recursion Pharmaceuticals, Inc. (RXRX) Institutional Ownership & Insider Trading

342 institutions reported holding Recursion Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 37 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 2.0B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

342 institutions held 67.6% of the shares. Across filers that reported both quarters, shares held changed +5.6%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	342	362	+5.6%	124	39	95	32
Mar 26	334	336	+5.6%	128	44	72	39
Dec 25	328	323	+0.9%	120	46	75	46
Sep 25	313	328	+6.8%	120	40	68	41
Jun 25	329	310	+0.9%	105	48	86	54
Mar 25	332	304	+0.7%	126	55	59	39
Dec 24	310	305	+15.7%	114	61	55	31
Sep 24	263	261	+3.9%	104	42	51	38

Recursion Pharmaceuticals, Inc. — questions

Who owns Recursion Pharmaceuticals, Inc. stock?: 342 institutions reported Recursion Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (9.4%), ARK Investment Management LLC (7.7%), STATE STREET CORP (6.5%).
Are Recursion Pharmaceuticals, Inc. insiders buying or selling?: 37 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.